Article Information
PubMed
Published By
Print ISSN
Online ISSN
History
- Received September 2, 2017
- Revision received September 24, 2017
- Accepted October 3, 2017
- Published online November 4, 2017.
Copyright & License
Copyright © 2017 The Author(s). Published by the International Institute of Anticancer Research.
Author Information
- HARUHIKO YAMAZAKI1⇑,
- HIROYUKI IWASAKI1,
- TOSHINARI YAMASHITA1,
- TATSUYA YOSHIDA1,
- NOBUYASU SUGANUMA1,
- TAKASHI YAMANAKA1,
- KATSUHIKO MASUDO2,
- HIROTAKA NAKAYAMA3,
- KAORI KOHAGURA3,
- YASUSHI RINO3 and
- MUNETAKA MASUDA3
- 1Department of Breast and Endocrine Surgery, Kanagawa Cancer Center, Yokohama, Japan
- 2Department of Breast and Thyroid Surgery, Yokohama City University Medical Center Minamiku, Yokohama, Japan
- 3Department of Surgery, Yokohama City University School of Medicine, Yokohama, Japan
- Correspondence to: Haruhiko Yamazaki, Department of Breast and Endocrine Surgery, Kanagawa Cancer Center, 2-3-2 Nakao, Asahiku, Yokohama, Kanagawa, Japan. Tel: +81 455202222, Fax: +81 455202202, e-mail: h.yamazaki0413{at}kcch.jp
Statistics from Altmetric.com
Cited By...
In this issue
Jump to section
Related Articles
Cited By...
- Inhibition of IL-17A Protects against Thyroid Immune-Related Adverse Events while Preserving Checkpoint Inhibitor Antitumor Efficacy
- Association Between Immune-related Adverse Events and Clinical Outcome Following Nivolumab Treatment in Patients With Metastatic Renal Cell Carcinoma
- The Impact of High-Dose Glucocorticoids on the Outcome of Immune-Checkpoint Inhibitor-Related Thyroid Disorders
- Efficacy and Toxicity of Pembrolizumab in Pediatric Metastatic Recurrent Melanoma